{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:27:11Z","timestamp":1776270431592,"version":"3.50.1"},"reference-count":32,"publisher":"Ubiquity Press, Ltd.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,16]]},"DOI":"10.5334\/tohm.1023","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T08:12:43Z","timestamp":1750061563000},"source":"Crossref","is-referenced-by-count":2,"title":["Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders"],"prefix":"10.5334","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7128-7043","authenticated-orcid":false,"given":"Sujal","family":"Manohar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Jacobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1790-3672","authenticated-orcid":false,"given":"Rebecca","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4129-3674","authenticated-orcid":false,"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7340-1660","authenticated-orcid":false,"given":"Mariam","family":"Hull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3285","reference":[{"key":"key20250616121240_B1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S1092852918001219","article-title":"Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?","volume":"23","year":"2018","journal-title":"CNS Spectr"},{"key":"key20250616121240_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852917000621","article-title":"Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less \u201cgo\u201d and more \u201cstop\u201d from the motor striatum for robust therapeutic effects","volume":"23","year":"2018","journal-title":"CNS Spectr"},{"key":"key20250616121240_B3","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders","volume":"11","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"key20250616121240_B4","first-page":"29","article-title":"A Brief Review on the Role of Vesicular Monoamine Transporter2 Inhibitors in Hyperkinetic Movement Disorders","volume":"15","year":"2021","journal-title":"Iran J Child Neurol"},{"key":"key20250616121240_B5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ncl.2020.01.004","article-title":"Treatment of Tardive Dyskinesia","volume":"38","year":"2020","journal-title":"Neurol Clin"},{"key":"key20250616121240_B6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14737175.2018.1403899","article-title":"Treatment options for chorea","volume":"18","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"key20250616121240_B7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"key20250616121240_B8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40265-018-0874-x","article-title":"Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors","volume":"78","year":"2018","journal-title":"Drugs"},{"key":"key20250616121240_B9","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors","year":"2019"},{"key":"key20250616121240_B10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/DDDT.S133205","article-title":"Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"12","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"key20250616121240_B11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ajhp\/zxz299","article-title":"Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia","volume":"77","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"key20250616121240_B12","first-page":"14","article-title":"Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review","year":"2024","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"key20250616121240_B13","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"key20250616121240_B14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","year":"2023","journal-title":"Lancet Neurol"},{"key":"key20250616121240_B15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/14737175.2021.1898948","article-title":"Clinical development of valbenazine for tics associated with Tourette syndrome","volume":"21","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"key20250616121240_B16","article-title":"Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial","volume":"4","year":"2021","journal-title":"JAMA Netw Open"},{"key":"key20250616121240_B17","volume-title":"JAMA Netw Open","year":"2021"},{"key":"key20250616121240_B18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/mds.29714","article-title":"Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta-Analysis","volume":"39","year":"2024","journal-title":"Movement Disorders"},{"key":"key20250616121240_B19","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1007\/s00415-023-11769-0","article-title":"Real-world experience with VMAT2 inhibitors in Tourette syndrome","volume":"270","year":"2023","journal-title":"J Neurol"},{"key":"key20250616121240_B20","unstructured":"Study Details|Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy|ClinicalTrials.gov. Accessed at: https:\/\/clinicaltrials.gov\/study\/NCT05206513."},{"key":"key20250616121240_B21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/WNF.0000000000000326","article-title":"Real-World Experience With VMAT2 Inhibitors","volume":"42","year":"2019","journal-title":"Clin Neuropharmacol"},{"key":"key20250616121240_B22","first-page":"e202","article-title":"Evaluating depression and suicidality in tetrabenazine users with Huntington disease","volume":"91","year":"2018","journal-title":"Neurology"},{"key":"key20250616121240_B23","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/mds.21063","article-title":"Tetrabenazine therapy of pediatric hyperkinetic movement disorders","volume":"21","year":"2006","journal-title":"Mov Disord"},{"key":"key20250616121240_B24","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","article-title":"Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature","volume":"34","year":"2012","journal-title":"Clin Ther"},{"key":"key20250616121240_B25","first-page":"28","article-title":"The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice","volume":"4","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"key20250616121240_B26","article-title":"Dissemination of VMAT-2 Inhibitors: A New Class Drug for Tardive Dyskinesia and Huntington Disease","volume":"15","year":"2025","journal-title":"Neurol Clin Pract"},{"key":"key20250616121240_B27","article-title":"Drug-induced parkinsonism: diagnosis and treatment","volume":"23","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"key20250616121240_B28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14737175.2024.2376107","article-title":"Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington\u2019s disease","volume":"24","year":"2024","journal-title":"Expert Rev Neurother"},{"key":"key20250616121240_B29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.410170217","article-title":"Tetrabenazine induces acute dystonic reactions","volume":"17","year":"1985","journal-title":"Ann Neurol"},{"key":"key20250616121240_B30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/cap.2019.0123","article-title":"Frequency and Correlates of Acute Dystonic Reactions After Antipsychotic Initiation in 441 Children and Adolescents","volume":"30","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"key20250616121240_B31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/mds.25278","article-title":"Analysis of CYP2D6 genotype and response to tetrabenazine","volume":"28","year":"2013","journal-title":"Mov Disord"},{"key":"key20250616121240_B32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/nmt-2018-0042","article-title":"Deutetrabenazine in the treatment of tardive dyskinesia","volume":"9","year":"2019","journal-title":"Neurodegener Dis Manag"}],"container-title":["Tremor and Other Hyperkinetic Movements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/storage.googleapis.com\/jnl-up-j-tohm-files\/journals\/1\/articles\/1023\/685009c07a210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:04:16Z","timestamp":1761552256000},"score":1,"resource":{"primary":{"URL":"https:\/\/tremorjournal.org\/articles\/10.5334\/tohm.1023\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,6,16]]}},"alternative-id":["10.5334\/tohm.1023"],"URL":"https:\/\/doi.org\/10.5334\/tohm.1023","relation":{},"ISSN":["2160-8288"],"issn-type":[{"value":"2160-8288","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"26"}}